Volume 16, Number 7—July 2010
Synopsis
Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia
Adrian R. Tramontana
, Biju George, Aeron C. Hurt, Joseph S. Doyle, Katherine Langan, Alistair B. Reid, Janet M. Harper, Karin Thursky, Leon J. Worth, Dominic E Dwyer, C. Orla Morrissey, Paul D.R. Johnson, Kirsty L. Buising, Simon James Harrison, John F. Seymour, Patricia E. Ferguson, Bin Wang, Justin T. Denholm, Allen C. Cheng, and Monica Slavin
, Biju George, Aeron C. Hurt, Joseph S. Doyle, Katherine Langan, Alistair B. Reid, Janet M. Harper, Karin Thursky, Leon J. Worth, Dominic E Dwyer, C. Orla Morrissey, Paul D.R. Johnson, Kirsty L. Buising, Simon James Harrison, John F. Seymour, Patricia E. Ferguson, Bin Wang, Justin T. Denholm, Allen C. Cheng, and Monica SlavinTable 2
Characteristics of 4 patients infected with oseltamivir-resistant pandemic influenza A (H1N1) virus isolates, Australia*†
| Characteristic | Patient no. |
|||
|---|---|---|---|---|
| 1 | 5 | 12 | 20 | |
| Within 100 days of HSCT‡ | No | Yes | No | – |
| Time to development of resistance, d | 22 | 11§ | 8 | 4 |
| Time of last positive NAT result, d | 28 | 16 | 8 | 4 |
| Change to zanamivir | Yes | No | No | No |
| Time to zanamivir, d | 36 | – | – | – |
| Died | Yes | Yes | No | No |
| LOS, d | 39 | 66 | 21 | 9 |
*HSCT, hematopoietic stem cell transplant; NAT, nucleic acid test; LOS, length of stay.
†Oseltamivir resistance was influenza virus with H275Y mutation.
‡Time from commencement of oseltamivir.
§Detected in bronchoalveolar lavage specimen with negative NAT on nasopharyngeal swab 3 d before first and 10 d after last bronchoscopy. This patient received oseltamivir for 5 d.
